Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yariv Mazor

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Mabs|January 27, 2015
Improving target cell specificity using a novel monovalent bispecific IgG designYariv Mazor, Vaheh Oganesyan, Chunning Yang, et al.
Mabs|February 26, 2026
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHORajesh K Mistry, Chendi Nui, Giulia Lambiase, et al.
Mabs|November 6, 2023
Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C<sub>H</sub>1-C<sub>λ</sub> interfaceJohn D Bagert, Vaheh Oganesyan, Chi-I Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal CancersAllison M Barrett, Zachary T Britton, Rosa A Carrasco, et al.
Mabs|August 29, 2024
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releaseJohn S Schardt, Even Walseng, Kim Le, et al.
Mabs|October 8, 2025
Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody designPeng Zhao, John Schardt, Chi-I Chiang, et al.
Cancer Discovery|January 9, 2021
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T CellsSimon J Dovedi, Matthew J Elder, Chunning Yang, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Mabs|January 27, 2015
Improving target cell specificity using a novel monovalent bispecific IgG designYariv Mazor, Vaheh Oganesyan, Chunning Yang, et al.
Mabs|February 26, 2026
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHORajesh K Mistry, Chendi Nui, Giulia Lambiase, et al.
Mabs|November 6, 2023
Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C<sub>H</sub>1-C<sub>λ</sub> interfaceJohn D Bagert, Vaheh Oganesyan, Chi-I Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal CancersAllison M Barrett, Zachary T Britton, Rosa A Carrasco, et al.
Mabs|August 29, 2024
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releaseJohn S Schardt, Even Walseng, Kim Le, et al.
Mabs|October 8, 2025
Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody designPeng Zhao, John Schardt, Chi-I Chiang, et al.
Cancer Discovery|January 9, 2021
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T CellsSimon J Dovedi, Matthew J Elder, Chunning Yang, et al.
Pageof 3